All lobbying filings

DAIICHI SANKYO, INC.

Lobbying for DAIICHI SANKYO INC

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $220,000.00 expenses · posted Oct 20, 2025

Official filing document

Bills named in this filing 2

HR 946
ORPHAN Cures Act
HR 2319
Women and Lung Cancer Research and Preventive Services Act of 2025

Lobbying activity 2

Health Issues

Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction

Taxation/Internal Revenue Code

Discussions regarding tax reform and tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.